Company Continues to Build Presence in Bozeman, MT as it Advances its Portfolio of Highly Selective Na1.7 Inhibitors for the Treatment of Pain

BOZEMAN, MONTANA, July 15, 2015 — SiteOne Therapeutics Inc. today announced the completion of an investment by Next Frontier Capital, a newly created venture fund in Bozeman, Montana ... Full Report →

SiteOne Therapeutics is developing novel therapeutics and diagnostics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing therapies, such as NSAIDs and opioids. Our lead therapeutic candidates are highly selective inhibitors of a voltage-gated sodium ion channel, Naᵥ1.7, which plays a critical role in the generation and conduction of pain signals.

SiteOne’s selective inhibitors of sodium channel 1.7 (Naᵥ1.7) are based on naturally occurring small molecules of marine origin. Our core technology allows the preparation of these compounds and pharmaceutically optimized analogues from simple starting materials. Because Naᵥ1.7 is validated as a target for pain treatment by human genetic conditions, it is an extremely high interest therapeutic target. Additional opportunities for our technology include development of a long-acting local analgesic and a diagnostic PET imaging agent.